Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protein delivery with infusion pumps

U Bremer1, C R Horres, M L Francoeur

  • 1Pharmetrix, Inc., Menlo Park, California 94025, USA.

Pharmaceutical Biotechnology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stratum corneum lipids of human epidermal keratinocyte air-liquid cultures: implications for barrier function.

Pharmaceutical research·1996
Same author

Characterization of low-temperature (i.e., < 65 degrees C) lipid transitions in human stratum corneum.

The Journal of investigative dermatology·1994
Same author

Polymorphism in stratum corneum lipids.

Biochimica et biophysica acta·1994
Same author

Topical penetration of piroxicam is dependent on the distribution of the local cutaneous vasculature.

Pharmaceutical research·1993
Same author

Local enhanced topical delivery (LETD) of drugs: does it truly exist?

Pharmaceutical research·1992
Same author

Physical methods for studying stratum corneum lipids.

Seminars in dermatology·1992
Same journal

Formulation development of protein dosage forms.

Pharmaceutical biotechnology·2002
Same journal

Regulatory considerations in the development of protein pharmaceuticals.

Pharmaceutical biotechnology·2002
Same journal

Quality assurance and quality control for biopharmaceutical products.

Pharmaceutical biotechnology·2002
Same journal

Fundamentals of freeze-drying.

Pharmaceutical biotechnology·2002
Same journal

Membrane filtration.

Pharmaceutical biotechnology·2002
Same journal

Fundamentals of thermal sterilization processes.

Pharmaceutical biotechnology·2002
See all related articles

Continuous infusion offers superior control over therapeutic effects compared to other delivery methods. Advancements in microelectronics and device design are making infusion more precise, programmable, and convenient for patients.

Area of Science:

  • Biomedical Engineering
  • Pharmacology
  • Drug Delivery Systems

Background:

  • Optimizing therapeutic effects often requires precise control of plasma drug levels.
  • Traditional delivery methods like oral administration, bolus injections, and depot delivery have significant limitations in achieving this precision.
  • Polypeptide therapeutics, in particular, benefit from controlled delivery due to their stability and absorption challenges.

Purpose of the Study:

  • To highlight the advantages of infusion over other drug delivery methods for polypeptides.
  • To discuss the role of technological advancements in improving infusion devices.
  • To explore future trends in drug infusion systems.

Main Methods:

  • Comparison of different polypeptide delivery methods (oral, bolus, depot, infusion).

Related Experiment Videos

  • Review of technological advancements impacting infusion devices, including microelectronics and micromachining.
  • Analysis of emerging infusion system designs (disposable, programmable, closed-loop, osmotically powered).

    • Main Results:

    • Infusion provides superior control over plasma levels compared to oral, bolus, or depot methods.
    • Microelectronics and micromachining are enabling smaller, more sophisticated infusion devices.
    • Future systems will be programmable, cost-effective, disposable, and potentially closed-loop, integrating biosensors.
    • Advancements in drug-device interfaces, such as prefilled cartridges, will improve usability and reduce errors.

    Conclusions:

    • Parenteral administration via infusion is a logical progression for polypeptide therapeutics.
    • Technological innovations are driving the development of advanced, patient-centric infusion systems.
    • The future of drug delivery involves personalized, automated, and highly controlled infusion therapies.